Clovis Oncology (CLVS) Misses Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- SanDisk shares fall on election and chip sector pressure
- Seagate Technology shares drop amid sector selloff
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
Clovis Oncology Announces First Quarter 2018 Operating Results
May 8, 2018 4:05 PM EDT$18.5M in Rubraca® sales for the first quarter of 2018, based on limited third-line BRCA-mutant ovarian cancer treatment label in U.S. All-comers and earlier-line ovarian cancer maintenance treatment indication approved in U.S. on April 6, 2018 CHMP adopted positive opinion for limited treatment indication in EU on March 23; Marketing Authorization by European Commission anticipated later this month European maintenance treatment filing for ovarian cancer planned for Q2 2018, potential CHMP opinion by year-end Initiated potential registrational trial (ATLAS) of Rubraca in advanced... More



